Novo Nordisk's Wegovy debuts in India: How it works, who it's for, and how much it costs
In a major development for India's fast-growing anti-obesity drug market, Novo Nordisk on Tuesday officially launched Wegovy, its highly anticipated weight-loss medication, marking a direct challenge to Eli Lilly's already available Mounjaro.
Wegovy will be rolled out as a once-weekly injectable, delivered via a FlexTouch pen-like device—a user-friendly, self-administered format that eliminates the need for vials or syringes. The drug is expected to be available in Indian pharmacies by the end of June 2025, according to Vikrant Shrotriya, Managing Director of Novo Nordisk India.
A market ripe for disruption
Novo Nordisk is betting big on India, where nearly 254 million people live with generalized obesity and 351 million with abdominal obesity.
The Danish pharma giant sees India as a key market for future sales, aiming to capture a large share of the country's ₹576 crore anti-obesity drug market, which has quadrupled from ₹133 crore in 2021, according to PharmaTrac.
'Obesity is not just a personal health concern — it is a chronic disease and a national epidemic that India cannot afford to ignore,' said Shrotriya. 'We are bringing Wegovy with the convenience of a world-class, state-of-the-art pen device, and an India-specific price.'
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
5 Books Warren Buffett Wants You to Read In 2025
Blinkist: Warren Buffett's Reading List
Undo
Source: iStock
How Wegovy works: Science behind the shot
Wegovy contains semaglutide, a GLP-1 receptor agonist, which mimics a natural hormone responsible for regulating blood sugar, reducing appetite, delaying gastric emptying, and improving satiety. While related drugs like Ozempic are used primarily for type 2 diabetes, Wegovy is specifically approved for chronic weight management in cases of morbid obesity.
The FlexTouch device allows patients to dial in their weekly dose, with four needles included in each monthly pack.
The drug works on key centers of the brain that regulate hunger and food cravings, promoting weight loss while offering additional metabolic benefits.
According to diabetologist Dr. V. Mohan, 'Clinical data on semaglutide demonstrates not just weight loss but also considerable improvement in cardiovascular risk factors and inflammatory markers. For Indians, where diabetes and heart disease are on the rise, access to such evidence-based therapy offers holistic benefits.'
India-specific pricing for Wegovy: Full dose list
With a pricing strategy tailored for the Indian market, Novo Nordisk is offering the same cost for the initial three dosing strengths:
Dose
Monthly Price (₹)
Per Dose (₹)
0.25 mg
₹17,345
₹4,366
0.5 mg
₹17,345
₹4,366
1 mg
₹17,345
₹4,366
1.75 mg
₹24,280
₹6,070
2.4 mg
₹26,015
₹6,503
By comparison, Mounjaro, which contains the dual-action compound tirzepatide, is priced more competitively:
Source: iStock
Mounjaro Dose
Monthly Price (₹)
2.5 mg
₹14,000
5 mg
₹17,500
Results comparable to bariatric surgery — but with caveats
Wegovy has demonstrated remarkable outcomes in clinical studies, positioning it as a breakthrough in the treatment of obesity and related conditions. Patients using the drug experienced an average weight loss of nearly 15%, with one in three shedding as much as 20% of their body weight. Beyond weight loss, Wegovy also significantly
reduces
the risk of major cardiovascular events such as heart attacks and strokes.
The drug also had notable benefits for liver health and showed improvement in liver fibrosis. However, the benefits of Wegovy are tied closely to continued use. Discontinuation often results in weight regain, and medical experts have raised concerns about potential muscle mass loss over time, underscoring the need for long-term management and monitoring.
Wegovy vs. Mounjaro: Key differences
Aspect
Wegovy (Semaglutide)
Mounjaro (Tirzepatide)
Mechanism
GLP-1 receptor agonist
Dual GIP and GLP-1 receptor agonist
Effect
Reduces appetite, delays gastric emptying
Enhances insulin secretion, appetite suppression
Indication
Approved for weight loss
Approved for diabetes, used off-label for weight loss
Dosing
Once a week via Flexpen
Once a week via single-dose vials
Price
₹17,345–₹26,015 per month
₹14,000–₹17,500 per month
One step to a healthier you—join Times Health+ Yoga and feel the change
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Study: Four out of 10 diabetics not aware of disease
Representative image NEW DELHI: Nearly four out of every 10 diabetics in India are unaware they have the disease, a new study published in Lancet Global Health has claimed. The study is based on an analysis of a survey carried out among 57,810 adults aged 45 years and older from 2017 to 2019. It found that 20% of adults aged 45 years and above in the country had diabetes. "Prevalence among men and women was similar, at 20%," the study said. It also found that prevalence of urban diabetes was approximately twice as high as in rural areas - which may reflect the differences in lifestyle and eating habits between people living in the two environments. The researchers from Mumbai-based International Institute of Population Sciences, the University of Michigan and the Harvard T H Chan School of Public Health, among others, have called for scaling up policies to better prevent, detect, manage, and control diabetes among middle-aged and older adults. India has the second highest number of adults with diabetes (20-79 yrs) in the world, and approximately 3% of the total deaths in India in 2019 were attributable to the disease. The number of people suffering from hypertension or high blood pressure is also on the rise, experts say. Easy access to medicines to manage the two conditions at early stages can help prevent serious complications. But studies suggest healthcare infrastructure in rural areas is far from ready. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like They Were So Beautiful Before; Now Look At Them; Number 10 Will Shock You Reportingly Undo A team of researchers from ICMR and WHO among others, recently carried out a survey in 19 districts of seven states to find out how well-equipped the community and primary health centres were to manage diabetes and hypertension. They found only about four in 10 sub-centres (SCs) were prepared to treat hypertension and diabetes. Many of the rest didn't even have basic medicines needed to manage the conditions. The survey found that out of 105 SCs assessed, nearly one-third had stockouts of tablet metformin (anti-diabetes medicine), and nearly half (45%) reported stockouts of tablet amlodipine, used to manage high blood pressure.
Business Standard
an hour ago
- Business Standard
Qure.ai Hosts High-Impact Policy Roundtable at Constitution Club of India to Champion AI in Public Health
VMPL New Delhi [India], August 13: a leading Indian deep-tech company and global healthcare AI pioneer, hosted a high-level roundtable on August 6 at the Constitution Club of India. The event brought together Members of Parliament, senior bureaucrats, public health leaders, and international development experts to discuss the role of artificial intelligence in strengthening India's public healthcare systems. The roundtable focused on bringing to light the diverse challenges faced by India's public health system, as voiced by policymakers from across the country. Members of Parliament representing rural and underserved constituencies highlighted gaps in early diagnosis, overburdened health workers, and limited infrastructure--issues that could be effectively addressed through AI-enabled tools. By grounding the conversation in real, on-the-ground realities, the event demonstrated how healthcare AI, when responsibly integrated, could serve as a practical solution to systemic problems. The gathering brought together prominent figures, including Members of Parliament Shri K. Francis George (Kottayam, Kerala), Shri Chatrapati Shahu Maharaj (Kolhapur, Maharashtra), and Shri Darshan Singh Chaudhary (Hoshangabad, Madhya Pradesh), as well as Shri Sudhaker Singh, former Agriculture Minister of Buxar, Bihar. Leaders from the global development sector--such as Mr. Harish Iyer (Gates Foundation), Dr. Jacob Creswell (Stop TB Partnership), Dr. Preet Deep Singh (APNA and Startup India), and Mr. Savio Rodrigues (founder, GoaChronicle)--also contributed to the discussion. Key points raised during the roundtable included the growing burden on frontline health workers, delays in disease detection, and the lack of scalable diagnostic infrastructure, particularly in underserved regions. Several speakers highlighted the urgent need to integrate AI-driven tools into India's healthcare framework, especially for early diagnosis of tuberculosis and non-communicable diseases. Shri Darshan Singh Chaudhary delivered a compelling statement in Hindi, calling AI "the need of the hour" for rural healthcare and urging greater focus on its implementation in resource-constrained areas. Though no formal partnerships were announced, the event generated substantial interest from Members of Parliament and senior officials to explore collaborative models with Attendees conveyed support for future pilots and initiatives, recognising the company's potential to deliver meaningful outcomes across public health programmes. "This roundtable was about action, not announcements," said Prashant Warier, CEO of "The presence of such diverse and respected voices shows that the ecosystem is ready to move from intent to impact. We're focused on real-world use cases, grounded policy support, and long-term commitment. Responsible AI is no longer optional; it has to be part of the foundation." recently named to the TIME100 Most Influential Companies list for 2025, is the only Indian company to feature in this year's edition. With over 4,500 deployments across more than 100 countries, including 1,200 sites in 25 Indian states, its AI solutions are used daily in real-world clinical settings, whether in rural mobile screening vans or high-volume emergency departments. The company's AI models, particularly those designed for chest X-ray interpretation, can detect conditions such as tuberculosis, lung nodules, lung cancer, heart failure and chronic obstructive pulmonary disease (COPD) within seconds. Qure's solutions have cleared findings and regulatory approvals in 92 chest X-ray AI solution has been evaluated by the World Health Organization (WHO) and included in its policy guidance for tuberculosis screening, including in settings without access to a human reader.. In addition to diagnostics, Qure's large language model-powered tools are helping healthcare providers generate structured reports and digitise medical records--critical functions for consistent and responsive care delivery. Qure's partnerships with AstraZeneca, Medtronic India, and Johnson & Johnson Medtech further demonstrate the platform's credibility and interoperability. These collaborations are not limited to product integration--they reflect the trust major Pharma and med-tech players place in Qure's technology and vision. With its latest Series D funding, is focused on deepening its presence in settings where the impact is immediate, from government-run primary health centres to tertiary hospitals. The company's solutions are designed to work within existing clinical workflows, ensuring that innovation complements rather than disrupts care delivery. The roundtable concluded on a strong note of alignment. Legislators, administrators, and public health experts echoed the belief that AI is not a futuristic add-on, but a present-day necessity to build more efficient, equitable, and scalable healthcare systems. The event has laid the groundwork for future collaborations, more policy engagement, and the continued recognition of as a quiet but essential partner in India's health innovation journey. About is a global health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Qure's solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. has presence in over 100 countries, with regional offices in London and New York. The company is also part of the 2025 class of Time100 Most Influential Companies by Time Magazine. (ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)
Time of India
2 hours ago
- Time of India
790 snakebite incidents reported in Mys dist in 2024
Mysuru: Compared to 2023, the number of snakebite incidents have more than doubled in most of Mysuru region in 2024. The data presented by health and family welfare department revealed that Mysuru district recorded four deaths due to snakebites in 2024. According to experts, most of these cases are reported from rural areas. According to the data presented by state health and family welfare minister, Dinesh Gundu Rao, to a question raised by MLC S Ravi in the ongoing legislative council session, as many as 790 snakebite cases were reported in Mysuru district in 2024. There were 323 cases in 2023 and 189 in 2022. A snake rescuer and former corporator, Balasubramanyam, popularly known as Snake Shyam, said most of the snakebites related calls and snake rescue are by farmers and farm labourers. "In urban areas, snakebite incidents are rare. But it is the highest in rural areas, especially in farms, paddy, and sugar cane fields," he explained. "Awareness about snakebites can prevent these incidents," he said. According to Bagadalapura Nagendra, president of Karnataka Rajya Raita Sangha and Hasiru Sene, most of the victims are either farmers or farm labourers. "Last year, a lot of snakebite incidents were reported among farmers, especially during farm work, as snakes came out of the anthills following heavy rainfall," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Austria: New Container Houses (Prices May Surprise You) Container House Search Now Undo "Snakebite incidents are common among farmers' families. The govt must start providing treatment for snakebites in taluk hospitals," he said. "Currently, farmers are paid Rs 2 lakh compensation in the event of a snakebite death. But many are missing out as submitting the copy of RTC is mandatory to get compensation. This rule must be changed," he said. BOX Dist-wise data of incidents* Districts | 2022 | 2023 | 2024 | Kodagu | 134 (1) | 163 (0) | 331 (1) | C'magaluru | 145 (0) | 291 (0) | 362 (3) | Ch'nagar | 35 (0) | 56 (0) | 261 (1) | Hassan | 171 (0) | 505 (0) | 850 (2) | Mandya | 156 (0) | 302 (4) | 763 (5) | S'mogga | 117 (0) | 274 (0) | 699 (6) | *(deaths in brackets) Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
